Long-Term Results after Treatment of Very Low-, Low-, and High-Risk Thyroid Cancers in a Combined Setting of Thyroidectomy and Radio Ablation Therapy in Euthyroidism
Open Access
- 9 July 2013
- journal article
- research article
- Published by Wiley in International Journal of Endocrinology
- Vol. 2013, 1-8
Abstract
Introduction. Differentiated thyroid cancer treatment usually consists of thyroidectomy and radio ablation in hypothyroidism 4-6 weeks after surgery. Replacing hypothyroidism by recombinant human thyroid stimulating hormone can facilitate radio ablation in euthyroidism within one week after surgery. The outcome of this approach was investigated.Methods. This is a prospective randomized trial to compare thyroidectomy and radio ablation within a few days after preconditioning with recombinant human thyroid stimulating hormone versus thyroidectomy and radio ablation separated by four weeks of L-T4withdrawal. Tumors were graded into very low-, low- , or high-risk tumors. Recurrence-free survival was confirmed at follow-up controls by neck ultrasound and serum thyroglobulin. Suspected tumor recurrence was treated by additional radio ablation or surgery. Quality-of-life questionnaires with additional evaluation of job performance and sick-leave time were used in all patients.Results. Radio ablation in euthyroidism in quick succession after thyroidectomy did not lead to higher tumor recurrence rates of differentiated thyroid cancers in any risk category and was significantly advantageous with respect to quality-of-life (), sick-leave time (), and job performance ().Conclusion. Recombinant human thyroid stimulating hormone can be used safely and with good efficacy to allow radio ablation under sustained euthyroidism within one week after thyroidectomy.
Keywords
Funding Information
- Deutsche Forschungsgemeinschaft
This publication has 25 references indexed in Scilit:
- Surgery and radioablation therapy combined: introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSHEuropean Journal of Endocrinology, 2009
- Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogenEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Three‐Week Thyroxine Withdrawal: A Thyroid‐Specific Quality of Life StudyThe Laryngoscope, 2006
- Thyroid Hormone Withdrawal in Patients with Differentiated Thyroid Carcinoma: A One Hundred Thirty-Patient Pilot Survey on Consequences of Hypothyroidism and a Pharmacoeconomic Comparison to Recombinant Thyrotropin AdministrationThyroid®, 2005
- Recombinant Human Thyrotropin is Helpful in the Follow-Up and 131 I Therapy of Patients with Thyroid Cancer: A Report of the Results and Benefits Using Recombinant Human Thyrotropin in Clinical RoutineThyroid®, 2005
- An Overview of the Management of Papillary and Follicular Thyroid CarcinomaThyroid®, 1999
- The influence of hypothyroidism on wound healing An experimental study1999
- Papillary and Follicular Thyroid CarcinomaNew England Journal of Medicine, 1998
- Quality-of-Life Changes in Patients with Thyroid Cancer After Withdrawal of Thyroid Hormone TherapyThyroid®, 1997
- Current trends in the management of well differentiated papillary thyroid carcinomaThe Journal of Clinical Endocrinology & Metabolism, 1996